Johnson & Johnson TALVEY — Sales to customers (Note 9) increased by 2.0% to $152.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 76.7%, from $86.00M to $152.00M. Over 2 years (FY 2023 to FY 2025), TALVEY — Sales to customers (Note 9) shows an upward trend with a 171.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market demand and successful commercialization of the product, while a decrease may signal competitive pressure or market saturation.
This metric represents the total net revenue generated from the sale of the TALVEY product line to external customers du...
Comparable to product-specific revenue disclosures found in the segment reporting of other large-cap pharmaceutical companies.
jnj_segment_talvey_sales_to_customers_note_9| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.75M | $15.75M | $15.75M | $15.75M | $58.00M | $69.00M | $75.00M | $85.00M | $86.00M | $106.00M | $122.00M | $149.00M | $152.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +268.3% | +19.0% | +8.7% | +13.3% | +1.2% | +23.3% | +15.1% | +22.1% | +2.0% |
| YoY Change | — | — | — | — | +268.3% | +338.1% | +376.2% | +439.7% | +48.3% | +53.6% | +62.7% | +75.3% | +76.7% |